Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...
Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...
Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...
The Gates Foundation, Novo Nordisk Foundation and Wellcome have announced the launch of the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI), a $50 million investment that will focus on ...
Bernstein analysts led by Florent Cespedes increased their price target on Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) stock to DKK620.00, up from DKK600.00, while maintaining a Market Perform rating.
Morgan Stanley (NYSE:MS) initiated coverage on shares of Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO), a global healthcare company specializing in diabetes care and other serious chronic conditions. The ...